Procedure Deep-Dive · November 21, 2026

Tuberous Sclerosis and Cosmetic Surgery: Facial Angiofibromas, Topical Sirolimus, Lasers, Ash-Leaf Spots, Kidney Tumors, LAM, and Seizures

The small pink bumps across the nose and cheeks get called acne for years, then rosacea, then just bad skin. For some adults they are facial angiofibromas, the most visible sign of tuberous sclerosis complex, a genetic condition that also builds tumors in the kidneys, cysts in the lungs, and seizures in the brain. Here is what the bumps are, what actually treats them, and why the organs nobody photographs matter more than the face before any elective operation.

By The Editorial Desk

18 min read

A woman in her late twenties with auburn hair pulled up in a loose bun, wearing an oversized cream waffle-knit sweater, seated at a wooden table beside a large bright window and holding a white ceramic mug in both hands, looking calmly toward the camera in soft natural daylight

She is 31 and has a folder of failed acne treatments. Benzoyl peroxide in high school, two rounds of antibiotics, a retinoid that made her peel, a dermatology resident who said rosacea and prescribed a gel, an aesthetician who extracted the bumps and made them bleed. The spots never behaved like acne. They do not come to a head, they do not come and go with her cycle, and they cluster in the creases beside her nose and across her cheeks and chin in a pattern that has stayed nearly the same since she was eight. She books a consultation for laser resurfacing because she is tired of covering them.

During the history she mentions, almost as an aside, that she had "a few seizures as a kid" that stopped by adolescence, that an ultrasound for back pain once found "fatty spots" on both kidneys, and that her mother has a rough, raised patch of skin on her lower back. A clinician who knows what to look for reaches for a Wood's lamp and finds four pale, leaf-shaped patches on her trunk that she never noticed.

That cluster is a textbook presentation of tuberous sclerosis complex, often shortened to TSC. The bumps on her face are facial angiofibromas, not acne. The fatty kidney spots are angiomyolipomas, benign tumors that can bleed. And because she is a woman with TSC, her lungs deserve a look before anyone puts her under general anesthesia.

A laser can genuinely help her face. It just should not be the first thing that happens, and it is not the whole treatment.

What tuberous sclerosis complex is, and why adults find out late

The short answer: tuberous sclerosis complex is a genetic condition in which a faulty TSC1 or TSC2 gene lets a growth pathway called mTOR run unchecked, producing benign growths in the skin, brain, kidneys, lungs, heart, and eyes, and many mildly affected adults are diagnosed only after a skin finding gets a second look.

The TSC1 and TSC2 genes make two proteins, hamartin and tuberin, that work together as a brake on mTOR, a signaling hub that tells cells when to grow and divide. When one copy of either gene is faulty from birth and the second copy fails in a particular cell, that cell loses the brake and builds a small, disorganized, benign growth called a hamartoma. Because this can happen in almost any organ, TSC looks different in every person who has it.

The condition is estimated to affect roughly 1 in 6,000 to 1 in 10,000 births, and the Tuberous Sclerosis Alliance estimates that about 50,000 people in the United States live with it. It is inherited in an autosomal dominant pattern, so an affected parent has a 50 percent chance of passing it to each child, but about two-thirds of cases arise from a new gene change with no family history at all. Some people are mosaic, meaning the change happened after conception and is present in only some of their cells. Mosaic patients often have milder, patchier disease, and they are among the adults most likely to reach their thirties without a diagnosis.

The diagnosis rests on a set of clinical criteria maintained by the International Tuberous Sclerosis Complex Consensus Group, most recently updated in 2021, along with genetic testing. Several of the major criteria are skin findings, which is why dermatologists and cosmetic providers are so often the first to suspect it:

  • Facial angiofibromas: firm, pink to red, smooth bumps over the nose, the creases beside it, the cheeks, and the chin. They usually appear in early childhood and multiply and enlarge around puberty.
  • Hypomelanotic macules (ash-leaf spots): pale, often leaf-shaped patches on the trunk and limbs, present from birth or infancy, most easily seen under a Wood's lamp in fair skin.
  • Fibrous cephalic plaque: a raised, rubbery, skin-colored or slightly yellow plaque, most often on the forehead or scalp, which patients frequently mistake for a birthmark or scar.
  • Shagreen patch: a thick, bumpy, orange-peel textured patch, classically on the lower back.
  • Ungual fibromas: small, firm growths that emerge from under or beside the toenails and fingernails, usually appearing in adolescence or adulthood and sometimes the only sign a mildly affected adult has.
  • Minor signs: clusters of tiny pale "confetti" spots, small pits in tooth enamel, and fibromas on the gums or inside the mouth.

Inside the body, the same process can produce cortical tubers and nodules in the brain, which drive epilepsy in the large majority of people with TSC; kidney angiomyolipomas and cysts; lymphangioleiomyomatosis (LAM), a cystic lung disease that occurs almost entirely in women; heart tumors called rhabdomyomas, which are common in infancy and usually shrink with time; and retinal growths. Many people with TSC also have learning, behavioral, or psychiatric differences that the TSC community groups under the name TAND (TSC-associated neuropsychiatric disorders). Severity runs from profound disability to an adult whose only signs are a few nose bumps and two nail fibromas.

For a cosmetic patient, the practical point is this: if you or your provider suspect TSC because of your skin, the next step is not a treatment plan for the skin. It is a referral, usually to a TSC clinic, genetics, or a dermatologist familiar with the condition, for confirmation and organ screening. If your skin findings were dismissed for years, a second consultation with someone who recognizes the pattern is entirely reasonable.

Facial angiofibromas: the bumps that are not acne

The short answer: facial angiofibromas are benign growths of blood vessels and fibrous tissue driven by the same mTOR overactivity behind the rest of TSC, and the single most important development in their treatment is a topical mTOR inhibitor, sirolimus, which can shrink and fade them and slow their return after procedures.

Angiofibromas appear in a large majority of people with TSC, with most studies putting the figure at roughly three-quarters or more. They are often mistaken for acne because of their location and color, and for rosacea because of their redness, but the differences are telling once you know them. Angiofibromas are smooth and dome-shaped, with no blackheads, whiteheads, or pustules. They are firm rather than tender. They do not flare and settle the way inflammatory acne does, they bleed easily when picked or shaved, and they tend to concentrate in the nasolabial folds and on the chin, places where adult acne is less dominant. The redness of rosacea and broken capillaries is usually flat and diffuse; angiofibromas are discrete bumps. A provider who extracts them, as the patient above experienced, gets bleeding and no improvement.

A few angiofibromas on their own do not prove TSC. Isolated lesions, sometimes called fibrous papules of the nose, are common in adults without any genetic condition, and multiple angiofibromas also occur in other inherited syndromes, including multiple endocrine neoplasia type 1 and Birt-Hogg-Dube syndrome. A biopsy can confirm what the bump is, and the overall pattern, the patient's history, and genetic testing establish why. Angiofibromas confined to one side of the face can be a clue to mosaic TSC.

Topical sirolimus changed the field. Sirolimus, also called rapamycin, is an mTOR inhibitor originally used by mouth to prevent rejection in kidney transplant patients, a drug many readers of our piece on chronic kidney disease and transplant medications will recognize. Applied to the skin, it targets the overactive pathway inside the angiofibromas directly. For years dermatologists used compounded creams and solutions; in 2022 the FDA approved a 0.2 percent sirolimus topical gel (sold as Hyftor) specifically for facial angiofibroma associated with TSC in patients six years and older. What patients should know:

  • It works most reliably on early, red, flat or small lesions. Redness often improves within weeks; size and number improve over months. Large, firm, long-standing fibrotic bumps respond less, which is where procedures come in.
  • It is a long-term treatment, not a cure. When patients stop, the lesions generally drift back over months. Most dermatologists think of it the way they think of a maintenance medication.
  • Side effects are usually local. Dryness, irritation, stinging, and acne-like bumps are the common complaints. Because it is an immune-modulating drug, it should not go on broken or infected skin, and sun protection matters.
  • Coverage and cost can be a fight. Insurers vary on approving the branded gel, and some patients still use compounded versions. That is a conversation for the prescribing dermatologist, not the laser clinic.
  • It matters most around procedures. Several studies have found that starting or continuing topical sirolimus after laser or surgical removal slows recurrence, which turns a procedure from a temporary fix into a more durable one.
"A laser can remove an angiofibroma. It cannot remove the reason it grew. The most durable results come from treating the pathway with sirolimus and treating the bumps that are already there with a procedure."

The emotional weight of these lesions deserves to be named. They sit in the center of the face, they began in childhood, and many patients spent adolescence hearing that they should wash more or stop eating chocolate. Treating them is not vanity. It is a legitimate part of TSC care, and the international consensus guidelines explicitly include treatment of facial angiofibromas, both for appearance and because the lesions can bleed, itch, and interfere with daily life. For adolescents, the considerations in our guide to cosmetic surgery for teenagers apply, but early topical treatment in TSC is a medical recommendation, not a cosmetic indulgence.

Lasers, shaves, and procedures for angiofibromas, ash-leaf spots, and other TSC skin lesions

The short answer: established, raised angiofibromas respond to vascular lasers, ablative lasers, shave removal, and electrosurgery, and the plaques and nail fibromas can be excised, but every one of these lesions tends to recur, so the plan should pair procedures with topical sirolimus and assume repeat sessions.

The choice of procedure depends on what the lesion looks like:

  • Red, flat, or early lesions: vascular lasers such as the pulsed dye laser target the blood vessels and reduce redness, similar to how these devices treat facial redness and broken capillaries and port-wine stains. They do little for thick, fibrous bumps.
  • Raised, firm, fibrotic lesions: ablative lasers, carbon dioxide or erbium, vaporize tissue and flatten the surface. The tradeoffs described in our explainer on ablative versus non-ablative laser resurfacing apply: more downtime, a real risk of scarring and pigment change, and a need for experience. Treating a dense field of nose and cheek lesions is closer to a surgical resurfacing than a lunchtime treatment.
  • Large individual lesions: shave removal with electrosurgical smoothing, radiofrequency devices, or simple excision can debulk the biggest bumps quickly, much as surgeons treat benign growths such as skin tags and seborrheic keratoses. Angiofibromas bleed more than most benign growths, which is worth expecting rather than fearing.
  • Combination plans: many experienced centers debulk with ablative laser or shave, follow with vascular laser for residual redness, and then start or resume topical sirolimus once the skin has healed.

Recurrence is the rule. Without ongoing mTOR-targeted treatment, angiofibromas commonly return after any destructive procedure, sometimes within a year or two, and many patients need multiple sessions over a lifetime. That is not a sign the procedure failed. It is the biology. A provider who promises one-and-done removal is either unfamiliar with TSC or overselling.

Skin tone changes the risk. Ablative lasers and electrosurgery carry a meaningful risk of darkening or lightening in medium and darker skin tones, the same concern discussed in our guide to acne scar treatment. Test spots, conservative settings, and careful sun protection matter. Scar-prone patients should hear an honest discussion of scar care before resurfacing a large area.

Ash-leaf spots are a different problem. Hypomelanotic macules are not missing pigment cells in the way vitiligo patches are; they have pigment cells that produce less pigment. They do not respond to the pigment lasers used for sun spots and pigmentation, which remove pigment rather than add it, and the repigmentation strategies discussed in our piece on vitiligo and cosmetic surgery have limited evidence in TSC. Some case reports describe modest improvement with topical sirolimus. For most patients, cosmetic camouflage and sun protection (so the surrounding skin does not tan and widen the contrast) remain the practical options. Some people with ash-leaf spots also notice a lock of white hair or white eyelashes, which a tinted brow or lash product handles easily.

Plaques, patches, and nails. A fibrous forehead plaque or a shagreen patch can be surgically excised when it is small enough to close well, or debulked with ablative laser, but both can recur, and the scar should be weighed against the plaque. Ungual fibromas can be painful, distort the nail, and catch on socks and gloves. They are removed surgically at the base, often with the help of a hand or podiatric surgeon, and they frequently return. Gum fibromas and enamel pits are a dental matter, and patients planning veneers, implants, or facial cosmetic work should tell their dentist about the diagnosis.

Injectables and other aesthetic work. TSC does not itself contraindicate neurotoxin, fillers, or most non-surgical treatments. The cautions are practical ones: do not inject through an angiofibroma or an irritated area treated with topical sirolimus, expect easy bleeding from lesions near the injection sites, and make sure any provider doing laser hair removal on the face or body knows which bumps and patches are TSC lesions so they are avoided or treated deliberately.

Kidney angiomyolipomas, LAM, and the organs a cosmetic surgeon never sees

The short answer: the leading causes of serious illness in adults with TSC are not on the skin; they are kidney angiomyolipomas that can bleed and lung disease called LAM that can collapse a lung, and both need to be known and managed before elective surgery.

Kidney angiomyolipomas. These benign tumors made of blood vessels, smooth muscle, and fat develop in the kidneys of most adults with TSC, typically multiple and on both sides. Small ones are watched. Larger ones, particularly those with enlarged, aneurysm-like blood vessels, carry a risk of sudden bleeding into or around the kidney, which can cause severe flank pain, a drop in blood pressure, and an emergency. Current guidelines favor regular kidney imaging, usually MRI, throughout life, and treatment of growing tumors with oral everolimus (an mTOR inhibitor that the FDA approved for this use) or with embolization, a procedure in which an interventional radiologist blocks the tumor's blood supply. Older approaches that removed kidney tissue are avoided when possible because they cost kidney function. Many adults with TSC also have kidney cysts and gradually declining kidney function, and some have an overlapping condition in which a large deletion affects both TSC2 and the neighboring polycystic kidney gene, producing early, severe cysts like those described in our piece on polycystic kidney disease and tummy tucks.

For cosmetic planning, that means:

  • Know your latest imaging. A surgeon planning a tummy tuck, liposuction, or any procedure with abdominal pressure, prone positioning, or significant blood pressure swings should know the size of your largest angiomyolipoma and whether it has been treated. A tumor flagged for intervention should be dealt with first.
  • Know your kidney function. Reduced function affects the choice and dose of anesthetic and pain medications, and anti-inflammatory painkillers (NSAIDs) may need to be avoided entirely.
  • Report flank pain immediately. After any operation, sudden flank or abdominal pain, blood in the urine, or lightheadedness is not "normal soreness" in a patient with angiomyolipomas. It needs urgent evaluation.

Lymphangioleiomyomatosis (LAM). LAM is a slowly progressive lung disease in which abnormal smooth muscle-like cells infiltrate the lungs and create thin-walled cysts. It occurs almost exclusively in women, and in TSC it is common: screening studies have found lung cysts in a substantial share of adult women with the condition, with the proportion rising with age, although many have mild disease without symptoms. LAM can also occur in women who do not have TSC. The guidelines recommend a baseline chest CT for women with TSC in early adulthood, and treatment with oral sirolimus, which the FDA approved for LAM in 2015, for patients whose lung function is declining.

LAM changes the cosmetic plan in specific ways:

  • Pneumothorax risk. Lung cysts can rupture and collapse a lung, and repeated collapses are a hallmark of LAM. Positive pressure ventilation under general anesthesia, and procedures near the chest wall, add to that risk. Pneumothorax is already a rare but recognized complication of breast augmentation and of nerve blocks placed along the ribs; in a patient with cystic lungs, the anesthesia team needs to know beforehand, a theme we covered in the context of Marfan syndrome and breast implants.
  • Lung function and recovery. Women with moderate or advanced LAM may have reduced oxygen levels and a harder recovery from general anesthesia, much as patients with COPD do. Pulmonary function testing before a major elective operation is reasonable.
  • Hormones. LAM tends to worsen in the estrogen-rich years and has been linked to pregnancy and estrogen exposure. Many LAM specialists advise avoiding estrogen-containing contraception and hormone therapy, which can matter for patients who were planning to restart birth control around surgery.
  • Travel. Patients who fly to another city for surgery should discuss air travel with their pulmonologist, since pressure changes during flight are a concern in cystic lung disease and a pneumothorax far from home is a serious problem.

The heart usually matters less in adults. Cardiac rhabdomyomas typically shrink over childhood, but some patients are left with rhythm abnormalities, including an extra electrical pathway that causes Wolff-Parkinson-White patterns. An ECG before anesthesia is a reasonable baseline.

Seizures, mTOR inhibitors, and anesthesia

The short answer: most adults with TSC who have epilepsy can undergo elective surgery safely, provided their seizure medications are never missed, drug interactions are checked, and any oral mTOR inhibitor is managed with their prescribing team because these drugs slow wound healing and raise infection risk.

Seizure control comes first. Epilepsy affects most people with TSC and often begins in infancy. Some adults are seizure-controlled on medication, some still have breakthrough seizures, some have had epilepsy surgery or carry a vagus nerve stimulator, and some, like the patient in the opening, outgrew their seizures. The perioperative rules we described in epilepsy and cosmetic surgery apply fully: take anti-seizure medications on the morning of surgery with a sip of water unless told otherwise, plan for doses during long procedures or overnight stays, avoid prolonged fasting and sleep deprivation, and make sure the anesthesia team knows the seizure type and the last seizure date. Elective surgery should wait if seizure control has recently worsened. A vagus nerve stimulator and the energy devices used in surgery need coordination, much like the precautions in our piece on pacemakers and energy devices.

Drug interactions are real. Several older anti-seizure drugs, including carbamazepine, phenytoin, and phenobarbital, speed up the liver enzymes that break down many medications, including some anesthetics, opioids, and oral everolimus and sirolimus. Some newer drugs used in TSC have their own interactions, including cannabidiol (an approved prescription form is used for TSC seizures), which can affect liver tests and the levels of other medications. Bring a complete medication list, including supplements, and do not let anyone add or stop a drug around surgery without checking with the neurologist.

Oral mTOR inhibitors and wound healing. Everolimus is approved in TSC for brain tumors called SEGAs, for kidney angiomyolipomas, and as an add-on treatment for seizures, and sirolimus is used for LAM. These drugs are a major advance, but they come with surgical consequences:

  • Delayed wound healing. mTOR inhibitors slow the cell growth that closes incisions. Transplant surgery literature links them to wound complications and lymph fluid collections, which is relevant to procedures with large undermined areas, such as abdominoplasty, liposuction, and breast surgery.
  • Infection and mouth sores. They modestly suppress the immune system and commonly cause mouth ulcers, which matters for intraoral incisions and lip procedures.
  • Cholesterol and blood sugar. They can raise both, which feeds into overall surgical risk.

Whether to hold an oral mTOR inhibitor before and after surgery, and for how long, is a judgment that belongs to the prescribing physician, not the cosmetic surgeon, because stopping can allow kidney tumors, lung disease, or brain growths to progress. The decision should be made deliberately and documented, the same way patients on other immune-modulating drugs coordinate around surgery. Topical sirolimus on the face is a different matter: very little reaches the bloodstream, but most surgeons will ask you to stop applying it to any area being operated on until the skin has healed.

Neuropsychiatric differences and consent. Many adults with TSC live with autism, ADHD, anxiety, learning disability, or intellectual disability. That does not exclude cosmetic treatment, but it changes how it should be done: plain-language explanations, enough time, attention to sensory sensitivity around dressings and compression garments, a realistic plan for following aftercare instructions, and, when the patient cannot consent independently, careful involvement of a legal guardian or supported decision-maker. Anxiety and confusion after anesthesia, discussed in our guide to brain fog after anesthesia, can be more pronounced and should be planned for.

Where and how. For a short angiofibroma procedure under local anesthesia, a dermatology office is usually appropriate. For general anesthesia in a patient with active epilepsy, significant LAM, large angiomyolipomas, reduced kidney function, or an oral mTOR inhibitor, the setting matters: an accredited facility with experienced anesthesia staff and a clear transfer plan, as discussed in our guides to anesthesia choice and the operative plan, outpatient facility accreditation, and hospital privileges. Some patients with complex disease are safest having elective procedures at a hospital affiliated with their TSC center.

The honest summary

Tuberous sclerosis complex is rare, but its most visible sign sits in the middle of the face, which means cosmetic providers meet undiagnosed patients more often than they realize. Smooth, firm pink bumps around the nose and chin that never behaved like acne, pale leaf-shaped patches on the trunk, a rubbery forehead plaque, a thick patch on the lower back, or fibromas growing from the nails should prompt a diagnosis before a treatment plan. A biopsy, a careful history, and genetic testing settle the question, and a confirmed diagnosis opens the door to organ screening that can be lifesaving.

For the skin itself, the news is genuinely good. Topical sirolimus, now FDA approved for TSC-related facial angiofibromas, can fade and shrink lesions and slow their return. Vascular lasers, ablative lasers, shave removal, and excision can clear established bumps and plaques. The honest framing is maintenance, not cure: the lesions tend to return, the most durable results pair procedures with ongoing topical treatment, and pigment and scarring risks deserve respect in darker skin.

For anything beyond a small office procedure, the face is the least important organ in the room. Kidney angiomyolipomas can bleed, LAM can collapse a lung and change how anesthesia is delivered, seizure medications cannot be missed and interact with other drugs, and oral mTOR inhibitors slow healing in ways that matter for large operations. None of that rules out cosmetic surgery for a stable, well-managed adult with TSC. It does mean the order is fixed: diagnosis, current organ screening, a written plan from the TSC team, a surgeon and anesthesiologist who understand the condition, and only then the procedure. If a provider wants to laser the bumps without asking about your kidneys or lungs, get a second consultation first.